Cyclooxygenase-2-dependent prostacyclin formation is regulated by low density lipoprotein cholesterol in vitro

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 6, 2002, Pages 983-988

  Smith, Layton Harris ^a   Boutaud, Olivier ^a   Breyer, Matthew ^a   Morrow, Jason D ^a   Oates, John A ^a   Vaughan, Douglas E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cholesterol; Cyclooxygenase; Endothelial; LDL; Prostacyclin

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DACTINOMYCIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROSTACYCLIN; PROSTACYCLIN SYNTHASE;

ARTICLE; CARDIOVASCULAR RISK; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEATH; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HEART INFARCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; STROKE;

ASPIRIN; CELLS, CULTURED; CHOLESTEROL; CHOLESTEROL, LDL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; EPOPROSTENOL; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RNA, MESSENGER; TRANSCRIPTION, GENETIC; UMBILICAL VEINS;

EID: 0036079525     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000019734.89917.35     Document Type: Article

References (42)

1. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
2. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial
3. Nitric oxide in atherosclerosis: Vascular protector or villain?
4. Prostacyclin and vascular function: Implications for hypertension and atherosclerosis
5. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes
6. Interaction of platelets with the vessel wall in the pathophysiology of sudden cardiac death
7. Clinical implications of prostaglandin and thromboxane A2 formation (1)
8. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo: Evidence derived from the study of peripheral arterial disease
9. Helsinki Heart Study: New perspectives in the prevention of coronary heart disease
10. Total serum cholesterol and ischemic heart disease risk in clinical trials and observational studies
11. Adenosine 3′:5′-cyclic monophosphate induces regulated secretion of tissue-type plasminogen activator and von Willebrand factor from cultured human endothelial cells
12. Prostaglandin 12 reduces activation of human arterial smooth muscle cells in-vivo
13. Platelet activation in unstable coronary disease
14. Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity
15. Characterization of prostacyclin synthesis in cultured human arterial smooth muscle cells, venous endothelial cells and skin fibroblasts
16. Human cyclooxygenase-2 cDNA
17. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2
18. Regulation of cyclooxygenase-2 pathway by HER2 receptor
19. Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells
20. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells: Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element
21. Cyclooxygenase in biology and disease
22. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
23. Risk of cardiovascular events associated with selective COX-2 inhibitors
24. Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men
25. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis
26. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2
27. Identification of authentic estrogen receptor in cultured endothelial cells: A potential mechanism for steroid hormone regulation of endothelial function
28. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene
29. Simplified assay for the quantification of 2,3-dinor-6-keto-prostaglandin F1 alpha by gas chromatography-mass spectrometry
30. Routine prostaglandin assay by GC-MS in multiwell tissue culture plates: Application to human synoviocytes and chondrocytes
31. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells
32. Increased thromboxane biosynthesis in type IIa hypercholesterolemia
33. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins
34. The influence of lipoproteins (LDL and HDL) on PG12-formation by isolated aortic preparations of rabbits
35. Oxidized low density lipoprotein suppresses expression of inducible cyclooxygenase in human macrophages
36. Oxidized low density lipoprotein stimulates prostacyclin production by adult human vascular endothelial cells
37. Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits
38. Prostacyclin modulates cholesteryl ester hydrolytic activity by its effect on cyclic adenosine monophosphate in rabbit aortic smooth muscle cells
39. Sterol regulation of fatty acid synthase promoter: Coordinate feedback regulation of two major lipid pathways
40. Regulated intramembrane proteolysis: A control mechanism conserved from bacteria to humans
41. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a
42. Nuclear sterol regulatory element-binding proteins activate genes responsible for the entire program of unsaturated fatty acid biosynthesis in transgenic mouse liver